Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) presented compelling clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for two novel multispecific antibody programs: nilvanstomig (ZG005), a PD-1/TIGIT bispecific antibody, and alveltamig (ZG006), a trispecific T-cell engager targeting CD3 and dual DLL3 epitopes.
Nilvanstomig (ZG005) – Phase II Hepatocellular Carcinoma Data
Study Design & Key Results
Parameter
ZG005 20 mg/kg + Bevacizumab
ZG005 10 mg/kg + Bevacizumab
Sintilimab + Bevacizumab (Control)
Patient Population
First-line advanced HCC
First-line advanced HCC
First-line advanced HCC
Progression-Free Survival
HR=0.35 (95% CI: 0.15–0.76)
HR=0.41 (95% CI: 0.18–0.89)
Reference
Risk Reduction
65% reduction in progression/death
59% reduction in progression/death
—
Statistical Significance
Met primary endpoint
Met primary endpoint
—
Safety Profile
Well tolerated, favorable
Well tolerated, favorable
Consistent with known profiles
The ZG005-005 Phase II trial demonstrated statistically significant improvements in progression-free survival for both nilvanstomig dose groups compared to the positive control arm, as assessed by independent review committee using RECIST v1.1 criteria.
Forward‑Looking Statements This brief contains forward-looking statements regarding clinical trial results, regulatory pathways, and commercial expectations. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and clinical trial variability.-Fineline Info & Tech
By Fineline Cube